临床前阿尔茨海默病的驾驶能力评估：目前的进展和未来的道路。

Driving assessment in preclinical Alzheimer's disease: progress to date and the path forward.

机构信息

Department of Biomedical Engineering, Schulich School of Engineering, University of Calgary, Room 221, 2500 University Drive NW, Calgary, AB, T2N 1N4, Canada.

Department of Geomatics Engineering, Schulich School of Engineering, University of Calgary, Calgary, Canada.

出版信息

Alzheimers Res Ther. 2022 Nov 8;14(1):168. doi: 10.1186/s13195-022-01109-1.

DOI:10.1186/s13195-022-01109-1

PMID:36348410

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9641948/

Abstract

BACKGROUND

Changes in driving behaviour may start at the preclinical stage of Alzheimer's disease (AD), where the underlying AD biological process has begun in the presence of cognitive normality. Here, we summarize the emerging evidence suggesting that preclinical AD may impact everyday driving behaviour. MAIN: Increasing evidence links driving performance and behaviour with AD biomarkers in cognitively intact older adults. These studies have found subtle yet detectable differences in driving associated with AD biomarker status among cognitively intact older adults.

CONCLUSION

Recent studies suggest that changes in driving, a highly complex activity, are linked to, and can indicate the presence of, neuropathological AD. Future research must now examine the internal and external validity of driving for widespread use in identifying biological AD.

摘要

背景

驾驶行为的改变可能始于阿尔茨海默病（AD）的临床前阶段，此时 AD 的潜在生物学过程已经在认知正常的情况下开始。在这里，我们总结了一些新出现的证据，表明临床前 AD 可能会影响日常驾驶行为。主要内容：越来越多的证据将驾驶表现和行为与认知正常的老年人群中的 AD 生物标志物联系起来。这些研究发现，在认知正常的老年人群中，与 AD 生物标志物状态相关的驾驶行为存在微妙但可察觉的差异。结论：最近的研究表明，驾驶行为的改变——一种高度复杂的活动——与 AD 的神经病理学有关，并可以表明 AD 的存在。现在必须进行未来的研究，以检验驾驶行为在识别生物 AD 方面的广泛应用的内部和外部有效性。